Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma
Background: Gemcitabine, alone or in combination with other agents, has become an important part of the standard of care for treatment of both resectable and unresectable/advanced pancreatic adenocarcinoma. Gemcitabine is generally considered to have a favorable toxicity profile, with myelosuppressi...
Main Authors: | Eiichiro So, Zachary D. Crees, Danielle Crites, Andrea Wang-Gillam |
---|---|
Format: | Article |
Language: | English |
Published: |
Mary Ann Liebert
2017-08-01
|
Series: | Journal of Pancreatic Cancer |
Subjects: | |
Online Access: | https://www.liebertpub.com/doi/full/10.1089/PANCAN.2017.0012 |
Similar Items
-
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01) -
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01) -
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
by: Ling-Wei Hii, et al.
Published: (2019-09-01) -
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
by: Reham Abdel-Wahab, et al.
Published: (2018-05-01)